Evidence map›Paper›PMID 33126405›Full record

ReviewToxins2020

Dimitri Poddighe, Luca Vangelista

Open access · goldAbstract readReview
In one paragraph

Review in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Journal of bacteriology · 2025
    Article
  4. Article
  5. Investigation into Antibiotic Resistance Profiles ofInfection and drug resistance · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cholecalciferol Exhibits no Antibacterial Effect onRecent advances in anti-infective drug discovery · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Biofilm in sino-nasal infectious diseases: the role nasal cytology in the diagnostic work up and therapeutic implications.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023
    Review
  17. Microbiology spectrum · 2023
    Article
  18. Article
  19. Article
  20. Perspectives in Therapy of Chronic Rhinosinusitis.Diagnostics (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Dimitri PoddigheDepartment of Medicine, Nazarbayev University School of Medicine, Nur-Sultan 010000, Kazakhstan.ORCID 0000-0001-6431-9334
Luca VangelistaDepartment of Biomedical Sciences, Nazarbayev University School of Medicine, Nur-Sultan 010000, Kazakhstan.ORCID 0000-0003-0764-5031
National Research Center for Maternal and Child Health · KZNazarbayev University · KZ

Funding

Ministry of Education and Science of the Republic of Kazakhstan AP05134810
6 · The paper itself

Abstract

Chronic rhinosinusitis (CRS) is thought to be a multifactorial disease that includes a direct involvement of bacteria that trigger inflammation and contribute to CRS pathogenesis.

Indexed as

Bacterial ToxinsLeukocidinsNasal PolypsRhinitisSinusitisStaphylococcal InfectionsAnimalsChronic DiseaseHumansBacterial ToxinsLeukocidinsCCR5chronic rhinosinusitis (CRS)LukEDnasal polypspersistent infectionStaphylococcus aureus

Identifiers

PMID33126405
PMCPMC7692112
OpenAlexW3094981707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.